查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
罕见肾臟病市场:产业趋势和到2035年的全球预测:依目标疾病,分子类型,生物类型,给药途径,治疗类型,地区,主要药物开发商和销售预测
市场调查报告书
商品编码
1479824

罕见肾臟病市场:产业趋势和到2035年的全球预测:依目标疾病,分子类型,生物类型,给药途径,治疗类型,地区,主要药物开发商和销售预测

Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications, Type of Molecule, Type of Biologics, Route of Administration, Key Geographical Regions, Leading Drug Developers and Sales Forecast
出版日期: | 出版商: Roots Analysis | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格

罕见肾臟病市场规模预计到 2024 年将达到 39 亿美元，并在 2024-2035 年预测期间以 11% 的复合年增长率扩张。

罕见肾臟疾病包括至少 150 种疾病。在欧洲，如果一种疾病的盛行率低于 2,000 人中就有 1 人，则被视为罕见疾病；而在美国，如果疾病影响的人数少于 20 万人，则被视为罕见疾病。值得注意的是，2020 年有 8,000 多人被诊断出患有罕见肾臟疾病，儘管需求惊人，但只有 500 人接受了治疗。研究表明，超过12%的肾衰竭患者患有罕见的肾臟疾病，导致慢性虚弱和发病。因此，该领域的各个利益相关者正在做出各种努力来开发针对这些病症的客製化疗法。此外，自 2019 年以来，约有 80 亿美元投资于致力于开发罕见肾臟疾病治疗方法的公司。然而，诊断和治疗的进展受到患者群体有限、缺乏预后生物标记、临床多样性和模型生物不足等因素的阻碍。为了应对这些课题，该领域取得了显着进展。

包括基因组定序和个人化治疗在内的精准医学的出现，促进了罕见肾臟疾病的标靶治疗。药物再利用涉及确定新的治疗标靶和利用现有药物的药理学特性，已成为一种具有成本效益的策略。此外，整合人工智慧（AI）和机器学习演算法来优化个人化治疗是一项重大技术进步。最近，多种针对罕见肾臟疾病各种适应症的药物已获得世界各地监管机构的批准。2023年，美国食品药物管理局（FDA）批准Elfabrio（由Protalix BioTherapeutics开发）用于治疗法布瑞氏症，Tarpeyo（由Calliditas Therapeutics开发）用于治疗IgA肾病变。考虑到与这些药物相关的广阔前景，私人和公共投资者都在关注罕见肾病市场，从而在预测期内刺激显着增长。

该报告调查了全球罕见肾病市场，并依目标疾病、分子类型、生物类型、给药途径、治疗类型、地区、地区提供了市场概况。

目录

第一章研究方法论

第 2 章. 经济和其他专案特定考虑因素

第3章执行摘要

第 4 章 简介

第五章市场状况

  • 罕见肾病治疗药物：市场现状

第六章 罕见肾臟病治疗：详细公司简介

第七章 罕见肾臟病治疗：公司简介

第八章企业竞争力分析

第 9 章 伙伴关係与合作

  • 章节概述
  • 合作模式
  • 治疗罕见肾臟疾病：伙伴关係与合作

第十章 融资与投资

第11章临床试验分析

第十二章临床和商业吸引力

第十三章 关键意见领袖

第14章案例研究

第十五章市场影响分析：驱动因素、限制因素、机会、课题

  • 章节概述
  • 市场驱动力
  • 市场限制
  • 市场机会
  • 市场课题
  • 结论

第十六章 罕见肾臟病市场

  • 章节概述
  • 主要假设及研究方法
  • 罕见肾臟病药物Ⅲ期临床试验的假设
  • 预测模型
  • 全球罕见肾臟病市场、历史趋势和到 2035 年的预测

第十七章 罕见肾臟病市场（依目标疾病）

第十八章罕见肾臟病市场（依分子类型）

第十九章：罕见肾臟病市场（依生物製剂类型）

第 20 章 罕见肾臟病市场（依给药途径）

第 21 章 罕见肾臟病市场（依治疗类型）

第22章罕见肾臟病市场（依地区）

第23章 罕见肾臟病市场、药品销售预测

第24章主要药物开发公司的罕见肾臟病市场

第25章高阶主管洞察

第26章附录一：表格数据

第二十七章 附录二：公司与组织名单

Product Code: RA100484

Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Fabry Disease, Immunoglobulin A Nephropathy, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney Disease, Lupus Nephritis and Others), Type of Molecule (Small Molecules and Biologics), Type of Biologics (Monoclonal Antibodies and Proteins), Route of Administration (Oral, Intravenous, Subcutaneous, and Others), Type of Therapy (Monotherapy, Combination Therapy), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World), Leading Drug Developers and Sales Forecast

The Rare Kidney Diseases Market is valued at USD 3.9 billion in 2024 growing at a CAGR of 11% during the forecast period 2024-2035.

Rare kidney diseases encompass a spectrum of conditions, accounting to at least 150 distinct disorders. In Europe, a condition is deemed rare if its prevalence falls below 1 in 2000 individuals, while in the US, it's classified as rare if fewer than 200,000 people are affected. Notably, in 2020, out of over 8,000 individuals diagnosed with rare kidney diseases, only 500 received treatment, despite the alarming need. Research reveals that over 12% of individuals with kidney failure are afflicted with rare kidney diseases, resulting in chronic debilitation and morbidity. Consequently, various stakeholders in this domain have taken various initiatives to advance therapeutics tailored for these conditions. Further, since 2019, approximately USD 8 billion has been invested in the companies dedicated to developing therapies for rare kidney diseases. Nonetheless, progress in diagnosis and treatment has been impeded by such factors, such as limited patient populations, absence of prognostic biomarkers, clinical diversity, and inadequate model organisms. In order to cater to these challenges, notable strides have been made in the field.

The advent of precision medicine, encompassing genomic sequencing and personalized therapies, has facilitated targeted interventions for rare kidney diseases. Drug repurposing, involving the identification of new therapeutic targets and harnessing the pharmacological properties of existing drugs, has emerged as a cost-effective strategy. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms in order to optimize personalized treatment stands out as a prominent technological advancement. Recently, several drugs targeting various indications of rare kidney diseases have garnered approval from regulatory authorities worldwide. In 2023, the Food and Drug Administration (FDA) sanctioned Elfabrio (developed by Protalix BioTherapeutics) for Fabry Disease and Tarpeyo (developed by Calliditas Therapeutics) for IgA Nephropathy. Given the promising prospects associated with these drugs, both private and public investors have turned their attention towards the rare kidney diseases market, fueling the substantial growth during the forecast period.

Key Market Segments

Type of Target Disease Indication

Atypical Hemolytic Uremic Syndrome

Fabry Disease

Immunoglobulin A Nephropathy

Focal Segmental Glomerulosclerosis

Autosomal Dominant Polycystic Kidney Disease

Lupus Nephritis

Others

Type of Molecule

Small Molecules

Biologics

Type of Biologic

Monoclonal Antibodies

Proteins

Route of Administration

Oral

Intravenous

Subcutaneous

Others

Type of Therapy

Monotherapy

Combination Therapy

Leading Drug Developers

Alexion Pharmaceuticals

Amicus Therapeutics

Aurinia Pharmaceuticals

GSK

Otsuka PharmaceuticalMallinckrodt Pharmaceuticals

Novartis

Otsuka Pharmaceutical

Roche

Sanofi

Travere Therapeutics

Other Players

Geography

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

A comprehensive examination of the current market landscape pertaining to rare kidney diseases, encompassing various parameters, including the year of establishment, company size (based on the employee count), location of headquarters, phase of development (discovery to marketed), route of administration (oral, intravenous, subcutaneous, and others), type of molecule (biologics and small molecules), subtype of biologics (monoclonal antibodies, proteins, cell and gene therapies, RNA, biosimilars, stem cells, and live biotherapeutic products), dosing frequency (single dose, multiple dose, combination), type of therapy (monotherapy and combination therapy), target patient population (children, adults, and elderly patients), and target indication (Lupus Nephritis, Immunoglobulin A, Nephropathy, Focal Segmental Glomerulosclerosis, Membranous Nephropathy, Fabry Disease, Autosomal Polycystic Kidney Disease, Nephrotic Syndrome, Alport Syndrome, Atypical Hemolytic Uremic Syndrome, and C3 Glomerulopathy).

Detailed profiles of leading companies (shortlisted based on the robustness of their drug portfolios) operating in the rare kidney diseases market. Each profile features the company overview (year of establishment, employee count, location of headquarters, and leadership team), financial information (if available), rare kidney disease portfolio specifics, recent advancements, and an insightful projection for the future.

Brief summaries of notable companies (shortlisted based on their robust drug portfolios) operating in the rare kidney diseases market. Each profile highlights a concise overview of the company (year of establishment, employee count, location of headquarters, and leadership team) and financial information (if available).

A comprehensive analysis of company competitiveness among key developers in the rare kidney diseases domain, considering various pertinent parameters. These include supplier robustness (evaluated by years of experience and company size), company competitiveness (assessed by the most advanced drug development phase, quantity of drugs developed, route of administration, and molecule type), and the breadth of indications targeted by each drug.

An exhaustive examination of the collaborations formed among stakeholders involved in this sector since 2019, encompassing licensing agreements, research and development collaborations, mergers and acquisitions, product development partnerships, commercialization agreements, distribution partnerships, joint ventures, supply agreements, service agreements, technology utilization agreements, process development agreements, and other pertinent arrangements.

An assessment of funding and investments directed towards companies focusing on rare kidney disease treatments, spanning venture capital investments, funds raised through initial public offerings (IPOs) and subsequent offerings, grants, private placements, as well as equity and debt financing. This analysis delves into funding occurrences from 2019 to 2023, shedding light on the increasing attention from the venture capital community and other strategic investors within this market.

A comprehensive examination of both active and ongoing clinical trials concerning the therapies for rare kidney diseases, focusing on various pertinent factors including the year of trial registration, trial status, trial phase, study design (masking type, intervention model type, and primary purpose), type of sponsor, the most active industry and non-industry players (based on trial count), geographical distribution, and the enrolled patient populations.

An extensive assessment of the clinical and commercial demand of medications aimed at treating rare kidney disorders, considering multiple pertinent factors such as the size of the target patient population, dosing frequency, and the strength of doses.

A thorough examination, accentuating the key opinion leaders (KOLs) engaged in investigating clinical trials associated with rare kidney diseases, considering various pertinent factors including type of KOL, affiliated organization, targeted disease indication, industry and non-industry affiliations, as well as the geographical distribution of KOLs. Moreover, the section emphasizes the most active KOLs, evaluated through both our proprietary and third-party scoring methodologies.

A case study showcasing enterprises providing kidney care services, including details such as their year of establishment, company size (measured by employee count), location of headquarters, and focus on specific medical conditions.

A comprehensive examination of recent expansions of the rare kidney diseases market, encompassing the identification and evaluation of primary catalysts, potential obstacles, emerging prospects, and prevailing hurdles.

A detailed assessment of the present market size, current opportunities within rare kidney diseases therapies, and the prospective growth trajectory of the rare kidney diseases market over the next decade. Drawing on various parameters including anticipated adoption trends and validated primary data, we've formulated an informed projection of market evolution till 2035. Additionally, the report outlines the expected distribution of both current and forecasted opportunities within the rare kidney diseases sector. To accommodate the potential future uncertainties and enhance the robustness of our model, we've presented three forecast scenarios: conservative, base, and optimistic, each representing distinct trajectories for growth within the rare kidney diseases market.

A detailed analysis on the factors influencing the growth of the Detailed projections of the current and future market for rare kidney disease therapeutics across types of target indications, such as Atypical Hemolytic Uremic Syndrome, Fabry Disease, Immunoglobulin A Nephropathy, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney Disease, Lupus Nephritis and others.

Detailed projections of the current and future rare kidney disease market based on type of molecule, such as small molecules and biologics.

Comprehensive projections of the current and future rare kidney diseases market based on the type of biologics, such as monoclonal antibodies and proteins.

Detailed projections of the current and future rare kidney disease market across the types of routes of administration, such as oral, intravenous, subcutaneous, and others.

Detailed predictions of the current and future rare kidney diseases market across types of therapy, such as monotherapy and combination therapy.

Comprehensive projections of the current and future rare kidney diseases industry across key geographical regions, such as North America, Europe, Asia-Pacific and the rest of the world.

Detailed projections of the current and future rare kidney disease market across the sales of forecasted drugs.

Comprehensive projections of the current and future revenues from the sales of around 20 top-selling drugs developed by the leading players in the rare kidney diseases market, including Alexion Pharmaceuticals, Amicus Therapeutics, Aurinia Pharmaceuticals, GSK, Otsuka Pharmaceutical and other players.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the Rare Kidney Diseases Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Alexion Pharmaceuticals

Chinook Therapeutics

Horizon Therapeutics

Jiangsu Hengrui Pharmaceuticals

Novartis

Omeros

Roche

Sanofi

Travere Therapeutics

ZyVersa Therapeutics

Advicenne

Apellis Pharmaceuticals

argenx

Astellas Pharma

Boehringer Ingelheim

Calliditas Therapeutics

GSK

Mallinckrodt Pharmaceuticals

Synlogic

Takeda

TABLE OF CONTENTS

1. RESEARCH METHODOLOGY

2. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3. EXECUTIVE SUMMARY

4. INTRODUCTION

  • 4.1. Overview of Kidney Diseases
    • 4.1.1. Key Historical Events related to Kidney Diseases
    • 4.1.2. Factors Contributing to Kidney Diseases
  • 4.2. Overview of Rare Kidney Diseases
    • 4.2.1. Types of Rare Kidney Diseases
    • 4.2.2. Challenges Associated with RKD Diagnosis and Treatment
  • 4.3. Selection of Therapeutic targets for Rare Kidney Diseases
  • 4.4. Technological Advancements in the Rare Kidney Diseases Domain
  • 4.5. Recent Developments in the Rare Kidney Diseases Domain
  • 4.6. Future Perspectives

5. MARKET LANDSCAPE

  • 5.1. Rare Kidney Disease Therapies: Market Landscape
    • 5.1.1. Analysis by Phase of Development
    • 5.1.2. Analysis by Route of Administration
    • 5.1.3. Analysis by Type Molecule
    • 5.1.4. Analysis by Target Disease Indication
    • 5.1.5. Analysis by Type of Biologic
    • 5.1.6. Analysis by Type of Therapy
    • 5.1.7. Analysis by Dosing Frequency
    • 5.1.8. Analysis by Target Patient Segment
    • 5.1.9. Key Facts on Drug Designation

6. RARE KIDNEY DISEASE THERAPIES: DETAILED COMPANY PROFILES

  • 6.1. Chapter Overview
    • 6.1.1. Alexion Pharmaceuticals
      • 6.1.1.1 Company Overview
      • 6.1.1.2 Financial Information
      • 6.1.1.3 Pipeline Portfolio
      • 6.1.1.4 Recent Developments and Future Outlook
    • 6.1.2. Chinook Therapeutics
      • 6.1.2.1 Company Overview
      • 6.1.2.2 Financial Information
      • 6.1.2.3 Pipeline Portfolio
      • 6.1.2.4 Recent Developments and Future Outlook
    • 6.1.3. Horizon Therapeutics
      • 6.1.3.1 Company Overview
      • 6.1.3.2 Financial Information
      • 6.1.3.3 Pipeline Portfolio
      • 6.1.3.4 Recent Developments and Future Outlook
    • 6.1.4. Jiangsu Hengrui Pharmaceuticals
      • 6.1.4.1 Company Overview
      • 6.1.4.2 Financial Information
      • 6.1.4.3 Pipeline Portfolio
      • 6.1.4.4 Recent Developments and Future Outlook
    • 6.1.5. Novartis
      • 6.1.5.1 Company Overview
      • 6.1.5.2 Financial Information
      • 6.1.5.3 Pipeline Portfolio
      • 6.1.5.4 Recent Developments and Future Outlook
    • 6.1.6. Omeros
      • 6.1.6.1 Company Overview
      • 6.1.6.2 Financial Information
      • 6.1.6.3 Pipeline Portfolio
      • 6.1.6.4 Recent Developments and Future Outlook
    • 6.1.7. Roche
      • 6.1.7.1 Company Overview
      • 6.1.7.2 Financial Information
      • 6.1.7.3 Pipeline Portfolio
      • 6.1.7.4 Recent Developments and Future Outlook
    • 6.1.8. Sanofi
      • 6.1.8.1 Company Overview
      • 6.1.8.2 Financial Information
      • 6.1.8.3 Pipeline Portfolio
      • 6.1.8.4 Recent Developments and Future Outlook
    • 6.1.9. Travere Therapeutics
      • 6.1.9.1 Company Overview
      • 6.1.9.2 Financial Information
      • 6.1.9.3 Pipeline Portfolio
      • 6.1.9.4 Recent Developments and Future Outlook
    • 6.1.10. ZyVersa Therapeutics
      • 6.1.10.1 Company Overview
      • 6.1.10.2 Financial Information
      • 6.1.10.3 Pipeline Portfolio
      • 6.1.10.4 Recent Developments and Future Outlook

7. RARE KIDNEY DISEASE THERAPIES: SHORT COMPANY PROFILES

  • 7.1. Chapter Overview
    • 7.1.1 Advicenne
      • 7.1.1.1 Company Overview
      • 7.1.1.2. Pipeline Portfolio
    • 7.1.2. Apellis Pharmaceuticals
      • 7.1.2.1 Company Overview
      • 7.1.2.2. Pipeline Portfolio
    • 7.1.3. argenx
      • 7.1.3.1 Company Overview
      • 7.1.3.2. Pipeline Portfolio
    • 7.1.4. Astellas Pharma
      • 7.1.4.1 Company Overview
      • 7.1.4.2. Pipeline Portfolio
    • 7.1.5. Boehringer Ingelheim
      • 7.1.5.1 Company Overview
      • 7.1.5.2. Pipeline Portfolio
    • 7.1.6. Calliditas Therapeutics
      • 7.1.6.1 Company Overview
      • 7.1.6.2. Pipeline Portfolio
    • 7.1.7. GSK
      • 7.1.7.1 Company Overview
      • 7.1.7.2. Pipeline Portfolio
    • 7.1.8. Mallinckrodt Pharmaceuticals
      • 7.1.8.1 Company Overview
      • 7.1.8.2. Pipeline Portfolio
    • 7.1.9. Synlogic
      • 7.1.9.1 Company Overview
      • 7.1.9.2. Pipeline Portfolio
    • 7.1.10. Takeda
      • 7.1.10.1 Company Overview
      • 7.1.10.2. Pipeline Portfolio

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1 Key Parameters and Scoring Criteria
  • 8.2. Analysis Methodology
  • 8.3. Rare Kidney Disease Therapies Developers: Company Competitiveness Analysis
    • 8.3.1. Rare Kidney Disease Therapies Developers based in North America (Peer Group I)
    • 8.3.2. Rare Kidney Disease Therapies Developers based in Europe (Peer Group II)
    • 8.3.3. Rare Kidney Disease Therapies Developers based in Asia-Pacific and Rest of the World (Peer Group III)

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Rare Kidney Disease Therapies: Partnerships and Collaborations
    • 9.3.1 Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Target Disease Indication
    • 9.3.5. Analysis by Type of Partner
    • 9.3.6. Most Active Players: Analysis by Number of Partnerships
    • 9.3.7. Analysis by Geography
      • 9.3.7.1. Local and International Deals
      • 9.3.7.2. Intercontinental and Intracontinental Deals

10. FUNDING AND INVESTMENTS

  • 10.1. Chapter Overview
  • 10.2. Types of Funding
  • 10.3. Rare Kidney Disease Therapies: Funding and Investments
    • 10.3.1. Analysis by Year of Investment
    • 10.3.2. Analysis by Amount Invested
    • 10.3.3. Analysis by Type of Funding
    • 10.3.4. Analysis of Amount Invested by Type of Funding
    • 10.3.5. Analysis of Amount Invested by Year and Type of Funding
    • 10.3.6. Analysis by Target Disease Indication
    • 10.3.7. Analysis by Geography
    • 10.3.8. Most Active Players: Analysis by Number of Instances
    • 10.3.9. Most Active Players: Analysis by Amount Invested
    • 10.3.10. Leading Investors: Analysis by Number of Instances

11. CLINICAL TRIAL ANALYSIS

  • 11.1. Analysis Methodology and Key Parameters
  • 11.2. Rare Kidney Disease Therapies: Clinical Trial Analysis
    • 11.2.1. Analysis by Trial Registration Year
    • 11.2.2. Analysis by Trial Status
    • 11.2.3. Analysis by Trial Registration Year and Trial Status
    • 11.2.4. Analysis by Trial Registration Year and Patients Enrolled
    • 11.2.5. Analysis by Trial Status and Patients Enrolled
    • 11.2.6. Analysis by Trial Phase
    • 11.2.7. Analysis by Study Design
    • 11.2.8. Analysis by Trial Status, Trial Phase and Geography
    • 11.2.9. Analysis by Type of Sponsor
    • 11.2.10. Analysis by Gender of Patients
    • 11.2.11. Most Active Industry Players: Analysis by Number of Trials
    • 11.2.12. Most Active Non-Industry Players: Analysis by Number of Trials
    • 11.2.13. Analysis by Geography

12. CLINICAL COMMERCIAL ATTRACTIVENESS

  • 12.1. Methodology and Parameters
  • 12.2. Key Parameters and Scoring
  • 12.3. Clinical and Commercial Attractiveness Analysis: Phase III Drugs Targeting Rare Kidney Diseases

13. KEY OPINION LEADERS

  • 13.1. Methodology and Key Parameters
  • 13.2. Rare Kidney Disease Therapies: Key Opinion Leaders (KOLs)
    • 13.2.1. Analysis by Type of KOL
    • 13.2.2. Analysis by Type of Organization
    • 13.2.3. Analysis by Target Disease Indication
    • 13.2.4. Analysis by Industry Affiliated Organization
    • 13.2.5. Analysis by Non-Industry Affiliated Organization
    • 13.2.6. Analysis by Geographical Location of KOLs
    • 13.2.7. Most Prominent KOLs: Peer Group 1 (Principal Investigators)
    • 13.2.8. Most Prominent KOLs: Peer Group 2 (Study Directors)
    • 13.2.9. Most Prominent KOLs: Peer Group 3 (Study Chairs)
    • 13.2.10. Most Prominent KOLs: Analysis by RA Score

14. CASE STUDY

  • 14.1. Scope and Key Parameters
  • 14.2. Rare Kidney Disorders: List of Kidney Care Providers
  • 14.3. Rare Kidney Disorders: Advantages of Kidney Care
  • 14.4. Rare Kidney Disorders: Recent Developments

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 15.1. Chapter Overview
  • 15.2. Market Drivers
  • 15.3. Market Restraints
  • 15.4. Market Opportunities
  • 15.5. Market Challenges
  • 15.6. Conclusion

16. RARE KIDNEY DISEASE MARKET

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Assumptions for Phase III Rare Kidney Disease Drugs
  • 16.4. Forecast Model
  • 16.5. Global Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2035
    • 16.5.1. Scenario Analysis

17. RARE KIDNEY DISEASE MARKET, BY TARGET DISEASE INDICATION

  • 17.1. Chapter Overview
  • 17.2. Rare Kidney Disease Market: Distribution by Target Disease Indication, 2024, 2030 and 2035
    • 17.2.1. Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome, till 2035
    • 17.2.2. Rare Kidney Disease Market for Fabry Disease, till 2035
    • 17.2.3. Rare Kidney Disease Market for Immunoglobulin A Nephropathy, till 2035
    • 17.2.4. Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis, till 2035
    • 17.2.5. Rare Kidney Disease Market for Autosomal Dominant Polycystic Kidney Disease, till 2035
    • 17.2.6. Rare Kidney Disease Market for Lupus Nephritis, till 2035
    • 17.2.7. Rare Kidney Disease Market for Others, till 2035

18. RARE KIDNEY DISEASE MARKET, BY TYPE OF MOLECULE

  • 18.1. Chapter Overview
  • 18.2. Rare Kidney Disease Market: Distribution by Type of Molecule, 2024, 2030 and 2035
    • 18.2.1. Rare Kidney Disease Market for Small Molecules, till 2035
    • 18.2.2. Rare Kidney Disease Market for Biologics, till 2035

19. RARE KIDNEY DISEASE MARKET, BY TYPE OF BIOLOGICS

  • 19.1. Chapter Overview
  • 19.2. Rare Kidney Disease Market: Distribution by Type of Biologic, 2024, 2030 and 2035
    • 19.2.1. Rare Kidney Disease Market for Monoclonal Antibodies, till 2035
    • 19.2.2. Rare Kidney Disease Market for Proteins, till 2035

20. RARE KIDNEY DISEASE MARKET, BY ROUTE OF ADMINISTRATION

  • 20.1. Chapter Overview
  • 20.2. Rare Kidney Disease Market: Distribution by Route of Administration, 2024, 2030 and 2035
    • 20.2.1. Rare Kidney Disease Market for Oral, till 2035
    • 20.2.2. Rare Kidney Disease Market for Intravenous, till 2035
    • 20.2.3. Rare Kidney Disease Market for Subcutaneous, till 2035
    • 20.2.4. Rare Kidney Disease Market for Others, till 2035

21. RARE KIDNEY DISEASE MARKET, BY TYPE OF THERAPY

  • 21.1. Chapter Overview
  • 21.2. Rare Kidney Disease Market: Distribution by Type of Therapy, 2024, 2030 and 2035
    • 21.2.1. Rare Kidney Disease Market for Monotherapy, till 2035
    • 21.2.2. Rare Kidney Disease Market for Combination Therapy, till 2035

22. RARE KIDNEY DISEASE MARKET, BY GEOGRAPHY

  • 22.1. Chapter Overview
  • 22.2. Rare Kidney Disease Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
    • 22.2.1. North America: Forecasted Estimates, till 2035
    • 22.2.2. Europe: Forecasted Estimates, till 2035
    • 22.2.3. Asia-Pacific: Forecasted Estimates, till 2035
    • 22.3.4. Rest of the World: Forecasted Estimates, till 2035

23. RARE KIDNEY DISEASES MARKET, SALES FORECAST OF DRUGS

  • 23.1. Chapter Overview
  • 23.2. Approved Rare Kidney Disease Therapies Market: Sales Forecast
    • 23.2.1. Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast
    • 23.2.2. Benlysta(R) / Belimumab Sales Forecast
    • 23.2.3. Elfabrio(R) / PRX-102 / Pegunigalsidase Alfa Sales Forecast
    • 23.2.4. FILSPARI(R) / Sparsentan / RE-021 Sales Forecast
    • 23.2.5. Galafold / Migalastat / AT1001 Sales Forecast
    • 23.2.6. LUPKYNIS(R) / Voclosporin Sales Forecast
    • 23.2.7. Sibnayal(R) / ADV7103 Sales Forecast
    • 23.2.8. Tarpeyo(R) / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast
    • 23.2.9. TERLIVAZ(R) / Terlipressin Sales Forecast
    • 23.2.10. Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast
    • 23.2.11. ULTOMIRIS(R) / Ravulizumab-cwvz Sales Forecast
  • 23.3. Phase III Rare Kidney Disease Therapies Market: Sales Forecast
    • 23.3.1. APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast
    • 23.3.2. Atacicept / VT-001 Sales Forecast
    • 23.3.3. Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast
    • 23.3.4. FILSPARI(R) / Sparsentan / RE-021 Sales Forecast
    • 23.3.5. IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG6299 Sales Forecast
    • 23.3.6. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
    • 23.3.7. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
    • 23.3.8. Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast
    • 23.3.9. Lucerastat / ACT 434964 / OGT 923 Sales Forecast
    • 23.3.10. MIL62 Sales Forecast
    • 23.3.11. Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast
    • 23.3.12. Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast
    • 23.3.13. Repagermanium / DMX-200 Sales Forecast
    • 23.3.14. Sibeprenlimab / VIS-649 Sales Forecast
    • 23.3.15. SNP-ACTH / SNP ACTH (1-39) Sales Forecast
    • 23.3.16. Telitacicept / RC18 Sales Forecast
    • 23.3.17. Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast
    • 23.3.18. Venglustat / Ibiglustat / GZ402671 Sales Forecast

24. RARE KIDNEY DISEASES MARKET, BY LEADING DRUG DEVELOPERS

  • 24.1. Chapter Overview
  • 24.2. Rare Kidney Diseases Market: Distribution by Leading Drug Developers, 2024 (USD Million)
  • 24.2. Rare Kidney Diseases Market: Distribution by Leading Drug Developers, 2035 (USD Million)

25. EXECUTIVE INSIGHTS

  • 25.1. Chapter Overview
  • 25.2. Company A
    • 25.2.1. Company Snapshot
    • 25.2.2. Interview Transcript: Chief Executive Officer
  • 25.3. Chapter Overview
  • 25.3. Company B
    • 25.3.1. Company Snapshot
    • 25.3.2. Interview Transcript: Associate BD Director

26 APPENDIX I: TABULATED DATA

27 APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 5.1 List of Rare Kidney Disease Therapies
  • Table 2.2 List of Rare Kidney Disease Therapies Developers
  • Table 9.1 Rare Kidney Disease Therapies: List of Partnerships and Collaborations, 2019-2023
  • Table 10.1 Rare Kidney Disease Therapies: List of Funding and Investments, 2019-2023
  • Table 11.1. Rare Kidney Disease Therapies: List of Clinical Trials, 2019-2023
  • Table 13.1. Rare Kidney Disease Therapies: List of Key Opinion Leaders (KOLs)
  • Table 16.1 Rare Kidney Disease Therapies: List of Forecasted Therapies
  • Table 26.1 Rare Kidney Diseases: Distribution by Phase of Development
  • Table 26.2 Rare Kidney Diseases: Distribution by Route of Administration
  • Table 26.3 Rare Kidney Diseases: Distribution by Type Molecule
  • Table 26.4 Rare Kidney Diseases: Distribution by Target Disease Indication
  • Table 26.5 Rare Kidney Diseases: Distribution by Type of Biologic
  • Table 26.6 Rare Kidney Diseases: Distribution by Type of Therapy
  • Table 26.7 Rare Kidney Diseases: Distribution by Dosing Frequency
  • Table 26.8 Rare Kidney Diseases: Distribution by Target Patient Segment
  • Table 26.9 Rare Kidney Diseases: Key Facts on Drug Designation
  • Table 26.10 Rare Kidney Diseases Developers: Distribution by Year of Establishment
  • Table 26.11 Rare Kidney Diseases Developers: Distribution by Company Size
  • Table 26.12 Rare Kidney Diseases Developers: Distribution by Location of Headquarters
  • Table 26.13 Most Active Players: Distribution by Number of Therapies
  • Table 26.14 AstraZeneca: Annual Revenues, FY 2018- FY 2023 (USD Billion)
  • Table 26.15 Chinook Therapeutics: Annual Revenues, FY 2018- Q1 FY 2023 (USD Million)
  • Table 26.16 Horizon Therapeutics: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
  • Table 26.17 Jiangsu Hengrui Pharmaceuticals: Annual Revenues, FY 2018-FY 2022 (CNY Million)
  • Table 26.18 Novartis: Annual Revenues, FY 2018-FY 2023 (USD Billion)
  • Table 26.19 Omeros: Annual Revenues, FY 2018-FY 2022 (USD Million)
  • Table 26.20 Roche: Annual Revenues, FY 2018-FY 2023 (CHF Billion)
  • Table 20.21 Sanofi: Annual Revenues, FY 2018-FY 2023 (EUR Billion)
  • Table 26.22 Travere Therapeutics: Annual Revenue, FY 2018-9M FY 2023 (USD Million)
  • Table 26.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
  • Table 26.26 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 26.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 26.26 Partnerships and Collaborations: Distribution by Target Disease Indication
  • Table 26.27 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 26.28 Most Active Players: Distribution by Number of Partnerships
  • Table 26.29 Partnerships and Collaborations: Local and International Deals
  • Table 26.30 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 26.31 Funding and Investments: Distribution by Year of Investment, 2019-2023
  • Table 26.32 Funding and Investments: Distribution by Amount Invested (USD Million)
  • Table 26.33 Funding and Investments: Distribution by Type of Funding
  • Table 26.34 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 26.35 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
  • Table 26.36 Funding and Investments: Distribution by Target Disease Indication
  • Table 26.37 Funding and Investments: Distribution by Geography
  • Table 26.38 Most Active Players: Distribution by Number of Instances
  • Table 26.39 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 26.40 Leading Investors: Distribution by Number of Instances
  • Table 26.41 Clinical Trial Analysis: Cumulative Year-wise Trend, 2019-2023
  • Table 26.42 Clinical Trial Analysis: Distribution by Trial Status
  • Table 26.43 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 26.44 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Table 26.45 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
  • Table 26.46 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 26.47 Clinical Trial Analysis: Distribution by Study Design
  • Table 26.48 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
  • Table 26.49 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 26.50 Clinical Trial Analysis: Distribution by Gender of Patients
  • Table 26.51 Most Active Industry Players: Analysis by Number of Trials
  • Table 26.52 Most Active Non-Industry Players: Analysis by Number of Trials
  • Table 26.53 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
  • Table 26.54 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
  • Table 26.55 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of KOL
  • Table 26.56 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of Organization
  • Table 26.57 Rare Kidney Disease Therapies KOL Analysis: Distribution by Target Disease Indication
  • Table 26.58 Rare Kidney Disease Therapies KOL Analysis: Distribution by Industry Affiliated Organization
  • Table 26.59 Rare Kidney Disease Therapies KOL Analysis: Distribution by Non-Industry Affiliated Organization
  • Table 26.60 Rare Kidney Disease Therapies KOL Analysis: Geographical Distribution of KOLs
  • Table 26.61 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
  • Table 26.62 Most Prominent KOLs: Peer Group 2 (Study Directors)
  • Table 26.63 Most Prominent KOLs: Peer Group 3 (Study Chairs)
  • Table 26.64 Most Prominent KOLs: Distribution by RA score
  • Table 26.65 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Base Scenario (USD Billion)
  • Table 26.66 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion )
  • Table 26.67 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion )
  • Table 26.68 Global Rare Kidney Disease Market: Distribution by Target Disease Indication, 2024, 2030 and 2035 (USD Billion )
  • Table 26.69 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome, Forecasted Estimates, till 2035 (USD Billion )
  • Table 26.70 Rare Kidney Disease Market for Fabry Disease, Forecasted Estimates, till 2035 (USD Billion )
  • Table 26.71 Rare Kidney Disease Market for Immunoglobulin A Nephropathy, Forecasted Estimates, till 2035 (USD Billion )
  • Table 26.72 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis, Forecasted Estimates, till 2035 (USD Billion )
  • Table 26.73 Rare Kidney Disease Market for Autosomal Dominant Polycystic Kidney Disease, Forecasted Estimates, till 2035 (USD Billion )
  • Table 26.74 Rare Kidney Disease Market for Lupus Nephritis, Forecasted Estimates, till 2035 (USD Billion )
  • Table 26.75 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion )
  • Table 26.76 Global Rare Kidney Disease Market: Distribution by Type of Molecule, 2024, 2030 and 2035 (USD Billion )
  • Table 26.77 Rare Kidney Disease Market for Small Molecules, Forecasted Estimates, till 2035 (USD Million)
  • Table 26.78 Rare Kidney Disease Market for Biologics, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.79 Global Rare Kidney Disease Market: Distribution by Type of Biologics, 2024, 2030 and 2035 (USD Billion)
  • Table 26.80 Rare Kidney Disease Market for Monoclonal Antibodies, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.81 Rare Kidney Disease Market for Proteins, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.82 Global Rare Kidney Disease Market: Distribution by Route of Administration, 2024, 2030 and 2035 (USD Billion)
  • Table 26.83 Rare Kidney Disease Market for Oral, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.84 Rare Kidney Disease Market for Intravenous, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.85 Rare Kidney Disease Market for Subcutaneous, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.86 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.87 Global Rare Kidney Disease Market: Distribution by Type of Therapy, 2024, 2030 and 2035 (USD Billion)
  • Table 26.88 Rare Kidney Disease Market for Monotherapy, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.89 Rare Kidney Disease Market for Combination Therapy, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.90 Global Rare Kidney Disease Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035 (USD Billion)
  • Table 26.91 Rare Kidney Disease Market in North America, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.92 Rare Kidney Disease Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.93 Rare Kidney Disease Market in Asia-Pacific, Forecasted Estimates, till 2035 (USD Billion)
  • Table 26.94 Rare Kidney Disease Market in Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
  • Table 27.95 Approved Rare Kidney Disease Therapies Market, Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast, till 2035 (USD Million)
  • Table 27.96 Approved Rare Kidney Disease Therapies Market, Benlysta(R) / Belimumab Sales Forecast, till 2035 (USD Million)
  • Table 27.97 Approved Rare Kidney Disease Therapies Market, Elfabrio(R) / PRX-102 / Pegunigalsidase Alfa Sales Forecast, till 2035 (USD Million)
  • Table 27.98 Approved Rare Kidney Disease Therapies Market, FILSPARI(R) / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
  • Table 27.99 Approved Rare Kidney Disease Therapies Market, Galafold / Migalastat / AT1001 Sales Forecast, till 2035 (USD Million)
  • Table 27.100 Approved Rare Kidney Disease Therapies Market, LUPKYNIS(R) / Voclosporin Sales Forecast, till 2035 (USD Million)
  • Table 27.101 Approved Rare Kidney Disease Therapies Market, Sibnayal(R) / ADV7103 Sales Forecast, till 2035 (USD Million)
  • Table 27.102 Approved Rare Kidney Disease Therapies Market, Tarpeyo(R) / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast, till 2035 (USD Million)
  • Table 27.103 Approved Rare Kidney Disease Therapies Market TERLIVAZ(R) / Terlipressin Sales Forecast, till 2035 (USD Million)
  • Table 27.104 Approved Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
  • Table 27.105 Approved Rare Kidney Disease Therapies Market ULTOMIRIS(R) / Ravulizumab-cwvz Sales Forecast, till 2035 (USD Million)
  • Table 27.106 Phase III Rare Kidney Disease Therapies Market APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast, till 2035 (USD Million)
  • Table 27.107 Phase III Rare Kidney Disease Therapies Market Atacicept / VT-001 Sales Forecast, till 2035 (USD Million)
  • Table 27.108 Phase III Rare Kidney Disease Therapies Market Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast, till 2035 (USD Million)
  • Table 27.109 Phase III Rare Kidney Disease Therapies Market FILSPARI(R) / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
  • Table 27.110 Phase III Rare Kidney Disease Therapies Market IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG62 Sales Forecast, till 2035 (USD Million)
  • Table 27.111 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
  • Table 27.112 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
  • Table 27.113 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
  • Table 27.114 Phase III Rare Kidney Disease Therapies Market Lucerastat / ACT 434964 / OGT 923 Sales Forecast, till 2035 (USD Million)
  • Table 27.115 Phase III Rare Kidney Disease Therapies MIL62 Sales Forecast, till 2035 (USD Million)
  • Table 27.116 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
  • Table 27.117 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
  • Table 27.118 Phase III Rare Kidney Disease Therapies Repagermanium / DMX-200 Sales Forecast, till 2035 (USD Million)
  • Table 27.119 Phase III Rare Kidney Disease Therapies Market Sibeprenlimab / VIS-649 Sales Forecast, till 2035 (USD Million)
  • Table 27.120 Phase III Rare Kidney Disease Therapies Market SNP-ACTH / SNP ACTH (1-39) Sales Forecast, till 2035 (USD Million)
  • Table 27.121 Phase III Rare Kidney Disease Therapies Market Telitacicept / RC18 Sales Forecast, till 2035 (USD Million)
  • Table 27.122 Phase III Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
  • Table 27.123 Phase III Rare Kidney Disease Therapies Market Venglustat / Ibiglustat / GZ402671 Sales Forecast, till 2035 (USD Million)
  • Table 27.124 Global Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2024 (USD Million))
  • Table 27.125 Global Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2035 (USD Million))

List of Figures

  • Figure 1.1 Research Methodology: Project Methodology
  • Figure 1.2 Research Methodology: Forecast Methodology
  • Figure 3.1 Executive Summary: Overall Market Landscape
  • Figure 3.2 Executive Summary: Partnerships and Collaborations
  • Figure 3.3 Executive Summary: Funding and Investment Analysis
  • Figure 3.4 Executive Summary: Clinical Trial Analysis
  • Figure 3.5 Executive Summary: Key Opinion Leaders
  • Figure 3.6 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 4.1 Key Historical Events
  • Figure 4.2 Factors Contributing to Rare Kidney Disorders
  • Figure 4.3 Types of Rare Kidney Diseases
  • Figure 4.4 Challenges Associated with RKD Diagnosis and Treatment
  • Figure 4.5 Selection of Therapeutic Targets for Rare Kidney Diseases
  • Figure 4.6 Technological Advancements in Rare Kidney Diseases Domain
  • Figure 5.1 Rare Kidney Diseases: Distribution by Phase of Development
  • Figure 5.2 Rare Kidney Diseases: Distribution by Route of Administration
  • Figure 5.3 Rare Kidney Diseases: Distribution by Type Molecule
  • Figure 5.4 Rare Kidney Diseases: Distribution by Target Disease Indication
  • Figure 5.5 Rare Kidney Diseases: Distribution by Type of Biologic
  • Figure 5.6 Rare Kidney Diseases: Distribution by Type of Therapy
  • Figure 5.7 Rare Kidney Diseases: Distribution by Dosing Frequency
  • Figure 5.8 Rare Kidney Diseases: Distribution by Target Patient Segment
  • Figure 5.9 Rare Kidney Diseases: Key Facts on Drug Designation
  • Figure 5.10 Rare Kidney Diseases Developers: Distribution by Year of Establishment
  • Figure 5.11 Rare Kidney Diseases Developers: Distribution by Company Size
  • Figure 5.12 Rare Kidney Diseases Developers: Distribution by Location of Headquarters
  • Figure 5.13 Most Active Players: Distribution by Number of Therapies
  • Figure 6.1 AstraZeneca: Annual Revenues, FY 2018- FY 2023 (USD Billion)
  • Figure 6.2 Chinook Therapeutics: Annual Revenues, FY 2018- Q1 FY 2023 (USD Million)
  • Figure 6.3 Horizon Therapeutics: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
  • Figure 6.4 Jiangsu Hengrui Pharmaceuticals: Annual Revenues, FY 2018-FY 2022 (CNY Million)
  • Figure 6.5 Novartis: Annual Revenues, FY 2018-FY 2023 (USD Billion)
  • Figure 6.6 Omeros: Annual Revenues, FY 2018-FY 2022 (USD Million)
  • Figure 6.7 Roche: Annual Revenues, FY 2018-FY 2023 (CHF Billion)
  • Figure 6.8 Sanofi: Annual Revenues, FY 2018-FY 2023 (EUR Billion)
  • Figure 6.9 Travere Therapeutics: Annual Revenue, FY 2018-9M FY 2023 (USD Million)
  • Figure 8.1 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in North America
  • Figure 8.2 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in Europe
  • Figure 8.3 Company Competitiveness Analysis: Rare Kidney Disease Therapies Developers based in Asia-Pacific and Rest of the World
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 9.4 Partnerships and Collaborations: Distribution by Target Disease Indication
  • Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 9.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.7 Partnerships and Collaborations: Local and International Deals
  • Figure 9.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 10.1 Funding and Investments: Distribution by Year of Investment, 2019-2023
  • Figure 10.2 Funding and Investments: Distribution by Amount Invested (USD Million)
  • Figure 10.3 Funding and Investments: Distribution by Type of Funding
  • Figure 10.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 10.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
  • Figure 10.6 Funding and Investments: Distribution by Target Disease Indication
  • Figure 10.7 Funding and Investments: Distribution by Geography
  • Figure 10.8 Most Active Players: Distribution by Number of Instances
  • Figure 10.9 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 10.10 Leading Investors: Distribution by Number of Instances
  • Figure 11.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2019-2023
  • Figure 11.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 11.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 11.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Figure 11.5 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
  • Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 11.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 11.8 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
  • Figure 11.9 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 11.10 Clinical Trial Analysis: Distribution by Gender of Patients
  • Figure 11.11 Most Active Industry Players: Analysis by Number of Trials
  • Figure 11.12 Most Active Non-Industry Players: Analysis by Number of Trials
  • Figure 11.13 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
  • Figure 11.14 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
  • Figure 12.1 Clinical and Commercial Attractiveness Analysis
  • Figure 13.1 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of KOL
  • Figure 13.2 Rare Kidney Disease Therapies KOL Analysis: Distribution by Type of Organization
  • Figure 13.3 Rare Kidney Disease Therapies KOL Analysis: Distribution by Target Disease Indication
  • Figure 13.4 Rare Kidney Disease Therapies KOL Analysis: Distribution by Industry Affiliated Organization
  • Figure 13.5 Rare Kidney Disease Therapies KOL Analysis: Distribution by Non-Industry Affiliated Organization
  • Figure 13.6 Rare Kidney Disease Therapies KOL Analysis: Geographical Distribution of KOLs
  • Figure 13.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
  • Figure 13.8 Most Prominent KOLs: Peer Group 2 (Study Directors)
  • Figure 13.9 Most Prominent KOLs: Peer Group 3 (Study Chairs)
  • Figure 13.10 Most Prominent KOLs: Distribution by RA score
  • Figure 16.1 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Base Scenario (USD Billion)
  • Figure 16.2 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion)
  • Figure 16.3 Global Rare Kidney Disease Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion)
  • Figure 17.1 Global Rare Kidney Disease Market: Distribution by Target Disease Indication, 2024, 2030 and 2035 (USD Billion)
  • Figure 17.2 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 17.3 Rare Kidney Disease Market for Fabry Disease, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 17.4 Rare Kidney Disease Market for Immunoglobulin A Nephropathy, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 17.5 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 17.6 Rare Kidney Disease Market for Autosomal Dominant Polycystic Kidney Disease, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 17.7 Rare Kidney Disease Market for Lupus Nephritis, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 17.8 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 18.1 Global Rare Kidney Disease Market: Distribution by Type of Molecule, 2024, 2030 and 2035 (USD Billion)
  • Figure 18.2 Rare Kidney Disease Market for Small Molecules, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 18.3 Rare Kidney Disease Market for Biologics, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 19.1 Global Rare Kidney Disease Market: Distribution by Type of Biologics, 2024, 2030 and 2035 (USD Billion)
  • Figure 19.2 Rare Kidney Disease Market for Monoclonal Antibodies, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 19.3 Rare Kidney Disease Market for Proteins, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 20.1 Global Rare Kidney Disease Market: Distribution by Route of Administration, 2024, 2030 and 2035 (USD Billion)
  • Figure 20.2 Rare Kidney Disease Market for Oral, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 20.3 Rare Kidney Disease Market for Intravenous, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 20.4 Rare Kidney Disease Market for Subcutaneous, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 20.5 Rare Kidney Disease Market for Others, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 21.1 Global Rare Kidney Disease Market: Distribution by Type of Therapy, 2024, 2030 and 2035 (USD Billion)
  • Figure 21.2 Rare Kidney Disease Market for Monotherapy, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 21.3 Rare Kidney Disease Market for Combination Therapy, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 22.1 Global Rare Kidney Disease Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035 (USD Billion)
  • Figure 22.2 Rare Kidney Disease Market in North America, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 22.3 Rare Kidney Disease Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 22.4 Rare Kidney Disease Market in Asia-Pacific, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 22.5 Rare Kidney Disease Market in Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
  • Figure 23.1 Approved Rare Kidney Disease Therapies Market, Agalsidase Beta BS I.V. Infusion / Agalsidase beta / JR-051 Sales Forecast, till 2035 (USD Million)
  • Figure 23.2 Approved Rare Kidney Disease Therapies Market, Benlysta(R) / Belimumab Sales Forecast, till 2035 (USD Million)
  • Figure 23.3 Approved Rare Kidney Disease Therapies Market, Elfabrio(R) / PRX-102 / Pegunigalsidase Alfa Sales Forecast, till 2035 (USD Million)
  • Figure 23.4 Approved Rare Kidney Disease Therapies Market, FILSPARI(R) / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
  • Figure 23.5 Approved Rare Kidney Disease Therapies Market, Galafold / Migalastat / AT1001 Sales Forecast, till 2035 (USD Million)
  • Figure 23.6 Approved Rare Kidney Disease Therapies Market, LUPKYNIS(R) / Voclosporin Sales Forecast, till 2035 (USD Million)
  • Figure 23.7 Approved Rare Kidney Disease Therapies Market, Sibnayal(R) / ADV7103 Sales Forecast, till 2035 (USD Million)
  • Figure 23.8 Approved Rare Kidney Disease Therapies Market, Tarpeyo(R) / Nef-301 / Nefigard-OLE / Nefecon / Kinpeygo Sales Forecast, till 2035 (USD Million)
  • Figure 23.9 Approved Rare Kidney Disease Therapies Market TERLIVAZ(R) / Terlipressin Sales Forecast, till 2035 (USD Million)
  • Figure 23.10 Approved Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
  • Figure 23.11 Approved Rare Kidney Disease Therapies Market ULTOMIRIS(R) / Ravulizumab-cwvz Sales Forecast, till 2035 (USD Million)
  • Figure 23.12 Phase III Rare Kidney Disease Therapies Market APL-2 / Pegcetacoplan/ Aspaveli / EMPAVELI / SYFOVRE Sales Forecast, till 2035 (USD Million)
  • Figure 23.13 Phase III Rare Kidney Disease Therapies Market Atacicept / VT-001 Sales Forecast, till 2035 (USD Million)
  • Figure 23.14 Phase III Rare Kidney Disease Therapies Market Atrasentan / CHK-01 / Atrasentan Hydrochloride / ABT-627 / Xinlay Sales Forecast, till 2035 (USD Million)
  • Figure 23.15 Phase III Rare Kidney Disease Therapies Market FILSPARI(R) / Sparsentan / RE-021 Sales Forecast, till 2035 (USD Million)
  • Figure 23.16 Phase III Rare Kidney Disease Therapies Market IONIS-FB-LRX / RO-7434656 / ASO Factor B / ISIS-696844 / RG62 Sales Forecast, till 2035 (USD Million)
  • Figure 23.17 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
  • Figure 23.18 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
  • Figure 23.19 Phase III Rare Kidney Disease Therapies Market Iptacopan / LNP 023 / LNP023-AAB / NVP-LNP023 / NVP-LNP023-AAB / NVP-LNP023-NX Sales Forecast, till 2035 (USD Million)
  • Figure 23.20 Phase III Rare Kidney Disease Therapies Market Lucerastat / ACT 434964 / OGT 923 Sales Forecast, till 2035 (USD Million)
  • Figure 23.21 Phase III Rare Kidney Disease Therapies MIL62 Sales Forecast, till 2035 (USD Million)
  • Figure 23.22 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
  • Figure 23.23 Phase III Rare Kidney Disease Therapies Obinutuzumab / Afutuzumab / GA101 / Gazyva / RO5072759 Sales Forecast, till 2035 (USD Million)
  • Figure 23.24 Phase III Rare Kidney Disease Therapies Repagermanium / DMX-200 Sales Forecast, till 2035 (USD Million)
  • Figure 23.25 Phase III Rare Kidney Disease Therapies Market Sibeprenlimab / VIS-649 Sales Forecast, till 2035 (USD Million)
  • Figure 23.26 Phase III Rare Kidney Disease Therapies Market SNP-ACTH / SNP ACTH (1-39) Sales Forecast, till 2035 (USD Million)
  • Figure 23.27 Phase III Rare Kidney Disease Therapies Market Telitacicept / RC18 Sales Forecast, till 2035 (USD Million)
  • Figure 23.28 Phase III Rare Kidney Disease Therapies Market Tolvaptan / Jynarque / Samsca / OPC-156 Sales Forecast, till 2035 (USD Million)
  • Figure 23.29 Phase III Rare Kidney Disease Therapies Market Venglustat / Ibiglustat / GZ402671 Sales Forecast, till 2035 (USD Million)
  • Figure 24.1 Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2024 (USD Million)
  • Figure 24.2 Rare Kidney Disease Market: Distribution by Leading Drug Developers (based on sales of rare kidney disease therapies in the year 2035 (USD Million)